Zydus Lifesciences’ (formerly Cadila Healthcare) managing director Sharvil Patel speaks to Scrip on a host of topics ranging from a focus on rare diseases to a fresh corporate identity and plans for launch of a two-dose version of the world’s first plasmid DNA vaccine that it developed against COVID-19. Patel also talks about his personal business journey as well as the importance of building organizational agility to deal with uncertainty that companies are increasingly having to deal with.